A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
Elaprase
Synonyms :
idursulfase
Class :
Metabolic enzymes
Dosage forms & Strengths:
Injectable solution
2 mg/ml
Administer dose of 0.5 mg/kg intravenously every week and infuse over 1 to 3 hours every week
Safety and efficacy are not seen in pediatrics
For <5 years old: Safety and efficacy not established
For ≥5 years old:
Administer dose of 0.5 mg/kg intravenously every week and infuse over 1 to 3 hours
>10%:
Pyrexia
Headache
Arthralgia
Limb pain
Pruritus
Visual disturbance
Wheezing
Abscess
Chest wall musculoskeletal pain
Musculoskeletal dysfunction
Urticaria
AE resulting from injury
Anxiety
Irritability
Atrial abnormality
Dyspepsia
Infusion site edema
Pruritic rash
Skin disorder
Superficial injury
Frequency undefined:
Loss of consciousness
Angioedema
Seizure
Cyanosis
Cardiac arrhythmia
Idursulfase is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
No adequate studies have been reported on the drug in pregnant women.
Breastfeeding warnings:
No data is available regarding the excretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: idursulfase
Pronounced: EYE-dur-SUL-fase.
Why do we use idursulfase?
Idursulfase is a metabolic enzyme. It is used to treat hunter syndrome.